Although we did not detect anti-NCAM1 autoantibodies associated with COVID-19, our results verify their specificity in diseases such as schizophrenia and membranous lupus nephritis, where their presence has been previously established (Caza et al., 2021, ; Shiwaku et al., 2022). Here, NCAM1 is linked to schizophrenia.